[Form 3/A] Picard Medical, Inc. Amended Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
Bernard Skaggs, Chief Financial Officer of Picard Medical, Inc. (PMI), filed an amended Form 3 reporting two employee stock option awards. The filing shows 102,239 options granted with a $0.71 exercise price (as adjusted) and 408,956 options granted with a $0.71 exercise price (as adjusted). Each grant has a vesting commencement date (first: February 21, 2023; second: November 27, 2023). For both grants one-quarter cliff vests on the first anniversary of the vesting commencement date, with the remainder vesting monthly over the following 36 months, subject to continued service. The exercise price and share amounts were adjusted to reflect a combined forward and reverse split resulting in an overall forward split of 1 for 2.1524. The form was signed by Emily Semon as attorney-in-fact on 08/28/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Amendments clarify option quantities and exercise price after stock splits; grants follow standard multi-year vesting schedules.
The filing documents two option grants to the CFO totaling 511,195 options (102,239 and 408,956) with an adjusted exercise price of $0.71. Vesting schedules include a one-quarter cliff then monthly vesting over 36 months, which aligns executive incentives with multi-year retention. The amendment corrects conversion/exercise-price details to reflect a combined forward and reverse split (overall forward split of 1 for 2.1524), demonstrating attention to accurate Section 16 reporting. No other securities or transactions are disclosed.
TL;DR: Governance disclosure is complete for the awards; timing and signature indicate proper Form 3/A correction and filing procedure.
The Form 3/A properly identifies the reporting person as CFO and corrects conversion pricing after corporate stock-split actions. Vesting terms are explicitly stated and contingent on continued service, a common structure for executive equity grants. The filing is signed by an attorney-in-fact, consistent with authorized filings. The disclosure does not include other compensatory or related-party transaction details.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (3)
- F1. On June 28, 2024, the reporting person was granted 102,239 options, with a vesting commencement date of February 21, 2023. One quarter of the options cliff vest upon the first anniversary of the vesting commencement date, and the remaining options vest ratably in equal monthly installments over the 36 months following the first anniversary of the vesting commencement date, generally subject to the continued service of the reporting person through each applicable vesting date.
- F2. As adjusted to reflect the Company's 1 for 2.2 forward stock split of the Company's common stock and the Company's 1.0221 for 1 reverse stock split of the Company's common stock, resulting in an overall forward stock split of 1 for 2.1524.
- F3. On June 28, 2024, the reporting person was granted 408,956 options, with a vesting commencement date of November 27, 2023. One quarter of the options cliff vest upon the first anniversary of the vesting commencement date, and the remaining options vest ratably in equal monthly installments over the 36 months following the first anniversary of the vesting commencement date, generally subject to the continued service of the reporting person through each applicable vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.